Avivagen Provides Update on Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Ottawa, ON / Business Wire/ May 6, 2022 – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”) announces that the TSX Venture Exchange has granted an extension of up to 30 days for completion of the balance of the Company’s […]

Avivagen Inc. Announces Closing Of First Tranche Of A Private Placement Of Shares And Warrants For Procees Of Up To $5.0 Million

AvivagenLogo

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Ottawa, ON / Business Wire/ April 28, 2022 – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune […]

Avivagen Announces AGM Results and Update to Shareholders Record Year of Progress for OxC-betaTM Adoption Worldwide

Supply agreement with AB Vista in United States, Brazil and Thailand compliments existing partnerships in Asia and Mexico Continued positive animal trial results leading to orders, new customer wins and growing recognition from the scientific community Ottawa, ON /Business Wire/ April 8, 2022 / Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Company”), a life sciences […]

Avivagen Inc. Announces Results for the First Quarter Ending January 31, 2022

Avivagen Q1 Results 2022

Ottawa, ON /Business Wire/ March 30, 2022/ Avivagen Inc.  (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, has announced its unaudited financial results for the first quarter of […]

Avivagen Announces Closing of Private Placement of Debentures and Shares

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. Ottawa, ON – March 28, 2022 — Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal […]

Avivagen to Attend CEM Sponsored Alpha North Conference

Ottawa, ON /Business Wire/ March 22, 2022 /- Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce that it will be a presenter […]

Avivagen Secures New Influential Customer in Mexico

Ottawa, ON /Business Wire/ March 8, 2022 /– Avivagen Inc.  (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce that a large, influential and industry-leading […]

Avivagen Announces Approval in Vietnam

Avivagen announces approval in Vietnam

Ottawa, ON /Business Wire/ February 22, 2022 /– Avivagen Inc.  (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce that Avivagen’s oxidized carotenoid-based feed additive […]

Avivagen Announces CEO Update to Shareholders

Ottawa, ON /Business Wire/ January 26, 2022 /– Avivagen Inc.  (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, announces a CEO update to shareholders. To […]

Avivagen Announces Appointment of James Nickerson as President

Ottawa, ON /Business Wire/ January 25, 2022 /– Avivagen Inc.  (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is excited to announce the appointment of James  (“Jamie”) Nickerson, […]